Virtual Library

Start Your Search

Sitthi Sukauichai



Author of

  • +

    EP1.16 - Treatment in the Real World - Support, Survivorship, Systems Research (ID 206)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Treatment in the Real World - Support, Survivorship, Systems Research
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.16-35 - Survival of Patients with Small Cell Lung Cancer at a Cancer Hospital in Thailand, 2007-2016 (Now Available) (ID 135)

      08:00 - 18:00  |  Presenting Author(s): Sitthi Sukauichai

      • Abstract
      • Slides

      Background

      To determine survival of small cell lung cancer (SCLC) patients treated at Chonburi Cancer Hospital (CCH), Thailand.

      Method

      The researcher conducted this retrospective study by review medical records of SCLC patients treated at CCH from Jan, 2007-Dec, 2016 and follow up until Dec, 2018.

      Result

      This study enrolled 35 patients with median follow up time 7.9 months. The median age of patients was 61.0. Patient characteristics were male (82.9%), history of smoking (91.4%), clinical SVC obstruction at initial treatment (28.6%), ECOG 0-1 (57.1%), ECOG 2-4 and no record ECOG (42.9%).

      Treatment

      Concurrent chemo

      +definitive TRT

      Sequential chemo

      +definitive TRT

      Sequential chemo

      +palliative TRT

      Palliative chemo.

      BSC

      +/-

      TRT

      Total

      N=35
      Stage Limited 4 4 3 0 1 12
      Extensive 1 3 3 11 5 23
      BSC; best supportive care, Chemo; chemotherapy, TRT; thoracic radiotherapy

      Treatment modality was shown in the table. The first two most common chemotherapy as first-line regimen was cisplatin/etoposide (n=18) and carboplatin/etoposide (n=10). Treatment response was CR 10.3%, PR 44.9%, SD 10.3%, PD 3.4 % and NA 31%. Prophylaxis cranial irradiation (PCI) was done in one patient.

      Overall survival (OS) of the patient received systemic chemotherapy and/or radiotherapy with limited and extensive stage was 17.77 (95%CI;15.22-20.32)(n=11) and 5.94 (95%CI; 2.60-9.23) (n=18) months, respectively, and those of patient received supportive care was 3.28 (95%CI;1.43-5.13)(n=6) months.

      surival of sclc.jpg

      Conclusion

      The OS of the limited stage SCLC patients at our hospital was comparable to landmark studies. Nevertheless, the small number of the patient received PCI and most received treatment as sequential chemo-radiation.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.